TY  - JOUR
AU  - McNeil, Lisa K
AU  - Donald, Robert G K
AU  - Gribenko, Alexey
AU  - French, Roger
AU  - Lambert, Nathaniel
AU  - Harris, Shannon L
AU  - Jones, Thomas R
AU  - Li, Sheng
AU  - Zlotnick, Gary
AU  - Vogel, Ulrich
AU  - Claus, Heike
AU  - Abad, Raquel
AU  - Vazquez-Moreno, Julio Alberto
AU  - Borrow, Ray
AU  - Findlow, Jamie
AU  - Taha, Muhamed-Kheir
AU  - Deghmane, Ala-Eddine
AU  - Caugant, Dominique A
AU  - Kriz, Paula
AU  - Musilek, Martin
AU  - Wang, Xin
AU  - Vuong, Jeni
AU  - Mayer, Leonard W
AU  - Pride, Michael W
AU  - Jansen, Kathrin U
AU  - Anderson, Annaliesa S
PY  - 2018
DO  - 10.1128/mBio.00036-18
SN  - 2150-7511
UR  - http://hdl.handle.net/20.500.12105/9138
AB  - Bivalent rLP2086 (Trumenba), a vaccine for prevention of Neisseria meningitidis serogroup B (NmB) disease, was licensed for use in adolescents and young adults after it was demonstrated that it elicits antibodies that initiate complement-mediated...
LA  - eng
PB  - American Society for Microbiology (ASM)
KW  - Neisseria meningitidis serogroup B
KW  - Factor H binding protein
KW  - Flow cytometry
KW  - Meningococcal antigen surface expression (MEASURE) assay
KW  - Vaccine
KW  - Anti-Bacterial Agents
KW  - Antibodies, Bacterial
KW  - Antigens, Bacterial
KW  - Bacterial Proteins
KW  - Blood Bactericidal Activity
KW  - Flow Cytometry
KW  - Humans
KW  - Meningococcal Vaccines
KW  - Microbial Viability
KW  - Neisseria meningitidis, Serogroup B
TI  - Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine
TY  - journal article
ER  -